Clinical trials: Cirrhosis, Liver, open to volunteers
Diabetes Mellitus, Type 2, Liver Fibrosis
Effect of an Early Time Restricted Eating Mediterranean Diet Compared to Naltrexone/Bupropion on Liver Fibrosis in People With Cardiometabolic Risk Factors in a Hospital Outpatient Clinic (MEDFAST-study)
In the Netherlands, there are many people with cardiometabolic diseases. More than half of these people also have fatty liver. This is a build-up of fat in the liver (steatosis) and can lead to long-term scarring (fibrosis) and…
- Conditions
- Diabetes Mellitus, Type 2, Liver Fibrosis, Liver Steatoses, Hepatic Steatosis
- Trial name
- MEDFAST (NCT06845345)
- Testing
- early time restricted Mediterranean diet, Mysimba
- Where
- Netherlands
- Volunteers
- 70 people
- Sponsor
- Carmen Dietvorst
Liver Cirrhosis
Faecal Microbiota Transplantation for Liver Cirrhosis
The purpose is to investigate the effect of faecal microbiota transplantation (FMT) on complications, progression, and mortality of patients with liver cirrhosis.
- Trial name
- CHiFT (NCT04932577)
- Testing
- Faecal microbiota transplantation
- Where
- Denmark
- Volunteers
- 220 people
- Sponsor
- University of Aarhus
MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, Cirrhosis
MASLD in Type 2 Diabetes in Primary Care - a Follow-up Study
The goal of this observational study is to understand how metabolic dysfunction-associated steatotic liver disease (MASLD) changes over time in individuals with type 2 diabetes who previously participated in the EPSONIP study.
- Conditions
- MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, Cirrhosis, Advanced Fibrosis, Sarcopenia
- Trial name
- EPSOMIP2 (NCT07312136)
- Where
- Sweden
- Volunteers
- 317 people
- Sponsor
- Linkoeping University
Intrahepatic Cholangiocarcinoma (Icc)
Adjuvant Therapy for High-Risk Intrahepatic Cholangiocarcinoma: A Real-World Study
This multicenter real-world study assesses the efficacy and safety of adjuvant therapies in postoperative intrahepatic cholangiocarcinoma (ICC) patients with high-risk recurrence factors.
- Trial name
- NCT07640048
- Testing
- Adebrelimab, Gemcitabine, Cisplatin
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Peking Union Medical College Hospital
Cirrhosis
"Anticipant"-TIPS After a First Portal-hypertension-related Complication in Cirrhosis
Further decompensation (FD) in cirrhosis represents a prognostic stage associated with an even higher mortality than that associated with the first decompensation.
- Trial name
- Ant-TIPS (NCT07889726)
- Testing
- TIPS, Standard of Care (SOC)
- Where
- 8 sites in France
- Volunteers
- 266 people
- Sponsor
- University Hospital, Toulouse
Liver Cancer
Development and Testing of a Patient-facing Educational Tool About Liver Cancer Prevention
To develop and test liver cancer prevention educational material.
- Trial name
- NCT07010315
- Testing
- Cognitive Testing, Usability Testing
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Decompensated Cirrhosis
Hospital @ Home Model of Care for Cirrhosis
The purpose of this study is to work with patients diagnosed with end-stage liver disease to understand their perspectives on the Health at Home (H@H) Program, including desired outcomes and expectations, perceived barriers, and…
- Trial name
- H@H (NCT06396897)
- Testing
- Indiana University Health Hospital at Home Program
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Indiana University
Decompensated Cirrhosis
National Collaborative Centre for Hepatic Regenerative Medicine (NC-CHRM): Single vs Repeated Cycle of Granulocyte Colony-Stimulating Factor (GCSF) & Darbepoetin in Early Decompensated Cirrhosis
Chronic liver disease is a growing health concern, with limited access to liver transplants. This study addresses the urgent need for alternatives by exploring regenerative therapies, like G-CSF, to boost the liver's natural…
- Trial name
- NC-CHRM (NCT07131280)
- Testing
- Gcsf, Darbepoetin, Standard Medical Treatment
- Where
- India
- Volunteers
- 110 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Decompensated Cirrhosis
Fecal Microbiome Transplantation in Cirrhosis: Trial in Patients With Decompensated Cirrhosis
This is a phase III, multicenter, double-blind, placebo-controlled, randomized clinical trial to evaluate the safety and efficacy of Fecal Microbiota Transplantation (FMT) from healthy subjects to patients with decompensated…
- Trial name
- LiverGut (NCT06533852)
- Testing
- Fecal Microbiome Transplantation (FMT)
- Where
- 8 sites in Spain
- Volunteers
- 190 people
- Sponsor
- Consorcio Centro de Investigación Biomédica en Red (CIBER)
Intrahepatic Cholangiocarcinoma (Icc)
Intraarterial Therapies Plus Tislelizumab Plus Lenvatinib Versus Tislelizumab Plus Gemcitabine-Cisplatin in Unresectable Intrahepatic Cholangiocarcinoma
This is a phase III, multicenter, open-label, randomized controlled trial designed to evaluate the efficacy and safety of arterially directed therapy in combination with tislelizumab plus lenvatinib compared with gemcitabine and…
- Trial name
- RAINBOW (NCT07691515)
- Testing
- Gemcitabine, Cisplatin, Tislelizumab
- Where
- 21 sites in China
- Volunteers
- 140 people
- Sponsor
- Zhejiang Cancer Hospital
Chronic Liver Disease, Cirrhosis
An Observational Study of Patients With Chronic Liver Disease
TARGET-Liver Disease (TARGET-LD) is an observational research study to conduct a comprehensive review of outcomes for patients with chronic liver disease (CLD).
- Trial name
- NCT05744713
- Testing
- Observational
- Where
- 10 sites in United States
- Volunteers
- 500,000 people
- Sponsor
- Target PharmaSolutions, Inc.
Ascites, Variceal Bleeding
VIATORR® TIPS Study Evaluating 6-10mm Diameters (VIATIPS)
This Registry will look at patients being treated with a transjugular intrahepatic portosystemic shunt (TIPS) procedure for portal hypertension.
- Conditions
- Ascites, Variceal Bleeding, Portal Hypertension Related to Cirrhosis
- Trial name
- VIATIPS (NCT07390344)
- Testing
- GORE® VIATORR® TIPS Endoprosthesis with Controlled Expansion (6-10mm)
- Where
- 3 sites in United States
- Volunteers
- 152 people
- Sponsor
- W.L.Gore & Associates
Cirrhosis, Splenectomy; Status
Effect of Laparoscopic Splenectomy on Lipid Profiles in Cirrhotic Patients With Hypersplenism (2-Year Follow-Up)
Patients with liver cirrhosis frequently exhibit dyslipidemia due to impaired hepatic lipid synthesis, altered bile acid metabolism, and portal hypertension.
- Conditions
- Cirrhosis, Splenectomy; Status, Hypersplenism, Lipid Profiles
- Trial name
- LS-LP-CH (NCT07588373)
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Northern Jiangsu People's Hospital
Carcinoma, Hepatocellular, Hepatitis C, Chronic
Digitalized Surveillance Management for Liver Cancer Risk Population in Improving Eearly Diagnosis Efficancy in Chinese Population (dSEARCH)
The goal of this study is to evaluate whether the standardized liver cancer risk stratification management can effectively improve the early diagnosis rate of liver cancer in the targeted risk population in China.
- Conditions
- Carcinoma, Hepatocellular, Hepatitis C, Chronic, Hepatitis B, Chronic, Cirrhosis, Liver
- Trial name
- dSEARCH (NCT05870969)
- Testing
- Liver cancer surveillance every 3 months, Liver cancer surveillance every 6 months, Liver cancer surveillance annually
- Where
- China
- Volunteers
- 20,000 people
- Sponsor
- Ruijin Hospital
Biliary Tract Cancers, Intrahepatic Cholangiocarcinoma (Icc)
Phase 2 Study of Daraxonrasib in Recurrent KRAS-Mutant Biliary Tract Cancer
The purpose of this study is to evaluate the anti-tumor efficacy of daraxonrasib monotherapy in patients with unresectable or advanced/metastatic, KRAS-mutant BTC who have progressed on or are intolerant of 1st line systemic…
- Conditions
- Biliary Tract Cancers, Intrahepatic Cholangiocarcinoma (Icc), Extrahepatic Cholangiocarcinoma, Gallbladder Carcinoma
- Trial name
- NCT07793253
- Testing
- Daraxonrasib
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Metabolic Dysfunction-associated Fatty Liver Disease, Hepatic Steatosis
Association of HsCAR with MAFLD and Liver Fibrosis: a Cross-sectional Study
The goal of this observational study is to investigate the associations between a novel inflammatory marker, high sensitivity C-reactiveprotein to albumin ratio (hsCAR), and steatosis and fibrosis of metabolic…
- Conditions
- Metabolic Dysfunction-associated Fatty Liver Disease, Hepatic Steatosis, Liver Fibrosis
- Trial name
- NCT05974904
- Testing
- high-sensitivity C-reactive protein to albumin ratio
- Where
- China
- Volunteers
- 7,000 people
- Sponsor
- Chongqing Medical University
Liver Cirrhoses, Hepatocellular Carcinoma (HCC)
A Comparative Study of MRI and Ultrasound for Detection of Primary Hepatocellular Carcinoma, Body Composition and Risk Factors for Decompensation in Liver Cirrhosis
DETECT-HCC-ESLD is a prospective multicenter study designed to examine early detection and risk stratification of hepatocellular carcinoma (HCC) in individuals with advanced liver disease.
- Conditions
- Liver Cirrhoses, Hepatocellular Carcinoma (HCC), Sarcopenia in Liver Cirrhosis, Portal Hypertension Related to Cirrhosis
- Trial name
- DETECT-HCC (NCT07291141)
- Where
- Sweden
- Volunteers
- 600 people
- Sponsor
- Mattias Ekstedt
Non-hepatobiliary Indications
EUS-Guided ATI and SWE in Individuals With Normal FibroScan
The goal of this observational study is to establish preliminary reference values for Endoscopic Ultrasound (EUS)-guided Attenuation Imaging (ATI) and Shear Wave Elastography (SWE) in adults undergoing diagnostic EUS for…
- Trial name
- EUS ATI&SWE (NCT07714941)
- Testing
- Endoscopic Ultrasound (EUS), EUS-guided Attenuation Imaging (ATI), EUS-Guided Shear Wave Elastography (SWE)
- Where
- India
- Volunteers
- 100 people
- Sponsor
- Asian Institute of Gastroenterology, India
Chronic Liver Disease and Cirrhosis
Impact of Liver Transplantation on Sexual Life and Function
Liver Transplantation (LT) is a lifesaving intervention with around 90% of recipients currently surviving the first postoperative year and subsequent life expectancy now exceeding 20 years.
- Trial name
- NCT07268196
- Testing
- No Treatment
- Where
- India
- Volunteers
- 100 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Variceal Bleeding, Ultrasonography
Ultrasound Prediction of Esophageal Variceal Bleeding Risk
This prospective observational study aims to evaluate the accuracy of using routine abdominal ultrasound to predict the risk of esophageal variceal bleeding in adult patients with liver cirrhosis.
- Conditions
- Variceal Bleeding, Ultrasonography, Esophageal Bleeding, Esophageal Varices
- Trial name
- NCT07571876
- Volunteers
- 165 people
- Sponsor
- Assiut University